Drug Safety

, Volume 37, Issue 5, pp 309–316 | Cite as

Comparative Safety and Efficacy of Proton Pump Inhibitors in Paediatric Gastroesophageal Reflux Disease

  • Jaroslaw Kierkus
  • Grzegorz Oracz
  • Bartosz Korczowski
  • Edyta Szymanska
  • Anna Wiernicka
  • Marek Woynarowski
Review Article

Abstract

Gastroesophageal reflux is one of the most common reasons for referrals to paediatricians or paediatric gastroenterologists. Gastric acid-buffering agents, mucosal surface barriers and gastric anti-secretory agents are the main groups of medications currently used for treating gastroesophageal reflux disease (GERD) in children. Recently, the use of proton pump inhibitors (PPIs) for the treatment of GERD in children has increased considerably. Their effectiveness in healing erosive oesophagitis in paediatric subjects and in improving GERD symptoms has been established in many studies. However, the effectiveness in other clinical conditions and the long-term safety of PPIs for paediatric GERD have not been fully established yet and thus are still under debate. Therefore, the aim of this article is to provide a comparative review of the efficacy, safety and tolerability of PPIs in paediatric GERD. The available data suggest that short-term use of PPIs is well tolerated. Adverse events tend to be of a mild-to-moderate nature, with headache being the most frequently reported treatment-related adverse event. However, further well-designed trials and observational studies are still needed to clarify the efficacy and safety of PPIs in the paediatric population, especially in infants under the age of 12 months.

References

  1. 1.
    Orenstein SR, Izadnia F, Khan S. Gastroesophageal reflux disease in children. Gastroenterol Clin N Am. 1999;28:947–69.CrossRefGoogle Scholar
  2. 2.
    Yellon RF, Goldberg H. Update on gastroesophageal reflux disease in pediatric airway disorders. Am J Med. 2001;111(Suppl 8A):78S–84S.PubMedCrossRefGoogle Scholar
  3. 3.
    Barron JJ, Tan H, Spalding J, Bakst AW, Singer J. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr. 2007;45:421–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Chiesa C, Anania C, Pacifico L, Olivero G, Osborn JF. Helicobacter pylori therapy in children: a focus on proton pump inhibitors. Chemotherapy. 2011;57:85–93.PubMedCrossRefGoogle Scholar
  5. 5.
    Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs. 2003;5:25–40.PubMedCrossRefGoogle Scholar
  6. 6.
    Turk H, Hauser B, Brecelj J, Vandenplas Y, Orel R. Effect of proton pump inhibition on acid, weakly acid and weakly alkaline gastro-esophageal reflux in children. World J Pediatr. 2013;9:36–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr. 2007;150:262–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006;117:e817–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955–60.PubMedCrossRefGoogle Scholar
  10. 10.
    Pashankar DS, Israel DM. Gastric polyps and nodules in children receiving long-term omeprazole therapy. J Pediatr Gastroenterol Nutr. 2002;35:658–62.PubMedCrossRefGoogle Scholar
  11. 11.
    Tytgat GN. Review article: long-term use of proton pump inhibitors in GORD—help or hindrance? Aliment Pharmacol Ther. 2001;15(Suppl 2):6–9.PubMedCrossRefGoogle Scholar
  12. 12.
    DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190–200.PubMedCrossRefGoogle Scholar
  13. 13.
    Romano C, Chiaro A, Comito D, Loddo I, Ferrau V. Proton pump inhibitors in pediatrics: evaluation of efficacy in GERD therapy. Curr Clin Pharmacol. 2011;6:41–7.PubMedCrossRefGoogle Scholar
  14. 14.
    van der Pol RJ, Smits MJ, van Wijk MP, Omari TI, Tabbers MM, Benninga MA. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics. 2011;127:925–35.PubMedCrossRefGoogle Scholar
  15. 15.
    Kearns GL, Winter HS. Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics. J Pediatr Gastroenterol Nutr. 2003;37(Suppl 1):S52–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors—emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13(Suppl 3):27–36.PubMedCrossRefGoogle Scholar
  17. 17.
    de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37:485–505.PubMedCrossRefGoogle Scholar
  18. 18.
    Treluyer JM, Gueret G, Cheron G, Sonnier M, Cresteil T. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. Pharmacogenetics. 1997;7:441–52.PubMedCrossRefGoogle Scholar
  19. 19.
    Omari T, Lundborg P, Sandstrom M, Bondarov P, Fjellman M, Haslam R, et al. Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease. J Pediatr. 2009;155:222–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Tammara BK, Sullivan JE, Adcock KG, Kierkus J, Giblin J, Rath N, et al. Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease. Clin Pharmacokinet. 2011;50:541–50.PubMedCrossRefGoogle Scholar
  21. 21.
    Zhang W, Kukulka M, Witt G, Sutkowski-Markmann D, North J, Atkinson S. Age-dependent pharmacokinetics of lansoprazole in neonates and infants. Paediatr Drugs. 2008;10:265–74.PubMedCrossRefGoogle Scholar
  22. 22.
    Kierkus J, Furmaga-Jablonska W, Sullivan JE, David ES, Stewart DL, Rath N, et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease. Dig Dis Sci. 2011;56:425–34.PubMedCrossRefGoogle Scholar
  23. 23.
    Andersson T, Hassall E, Lundborg P, Shepherd R, Radke M, Marcon M, et al. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group. Am J Gastroenterol. 2000;95:3101–6.PubMedCrossRefGoogle Scholar
  24. 24.
    James L, Walson P, Lomax K, Kao R, Varughese S, Reyes J, et al. Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study. Clin Ther. 2007;29:2082–92.PubMedCrossRefGoogle Scholar
  25. 25.
    Khoshoo V, Edell D, Thompson A, Rubin M. Are we overprescribing antireflux medications for infants with regurgitation? Pediatrics. 2007;120:946–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Omari T, Davidson G, Bondarov P, Naucler E, Nilsson C, Lundborg P. Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1–24 months old with symptoms of gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2007;45:530–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr. 2009;154:514–20.PubMedCrossRefGoogle Scholar
  28. 28.
    Springer M, Atkinson S, North J, Raanan M. Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year. Paediatr Drugs. 2008;10:255–63.PubMedCrossRefGoogle Scholar
  29. 29.
    Winter H, Kum-Nji P, Mahomedy SH, Kierkus J, Hinz M, Li H, et al. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1–11 months old with symptomatic GERD. J Pediatr Gastroenterol Nutr. 2010;50:609–18.PubMedCrossRefGoogle Scholar
  30. 30.
    Sherbaniuk RW, Wensel R, Trautman A, Grace M, Lentle B, Walker K, et al. Gastrin, gastric emptying, and gastroesophageal reflux after ranitidine. J Clin Gastroenterol. 1983;5:239–44.PubMedCrossRefGoogle Scholar
  31. 31.
    Treem W, Hu P, Sloan S. Normal and proton pump inhibitor-mediated gastrin levels in infants 1 to 11 months old. J Pediatr Gastroenterol Nutr. 2013;57:520–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Moore DJ, Tao BS, Lines DR, Hirte C, Heddle ML, Davidson GP. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr. 2003;143:219–23.PubMedCrossRefGoogle Scholar
  33. 33.
    Comer G, Baker R, Tsou V, et al. Randomized, double-blind clinical outcomes, safety, and tolerability study of pantoprazole delayed-release granules in children aged 1 to 5 years with endoscopically proven symptomatic gastroesophageal reflux disease (GERD). Gastroenterology. 2009;136:A-444 Abstract M1909.Google Scholar
  34. 34.
    Winter H, Gunasekaran T, Tolia V, et al. Esomeprazole for the treatment of GERD in infants ages 1–11 months. J Pediatr Gastroenterol Nutr. 2012;55(1):14–20.PubMedCrossRefGoogle Scholar
  35. 35.
    Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009;49:498–547.PubMedCrossRefGoogle Scholar
  36. 36.
    Omari TI, Haslam RR, Lundborg P, Davidson GP. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatr Gastroenterol Nutr. 2007;44:41–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Hussain S, Kierkus J, Hu P, Hoffman D, Lekich R, Sloan S, et al. Safety and efficacy of delayed release rabeprazole in 1 to 11 month-old infants with symptomatic GERD. J Pediatr Gastroenterol Nutr. 2014;58(2):233–43.Google Scholar
  38. 38.
    Orenstein SR, Shalaby TM, Cohn JF. Reflux symptoms in 100 normal infants: diagnostic validity of the Infant Gastroesophageal Reflux Questionnaire. Clin Pediatr (Phila). 1996;35:607–14.CrossRefGoogle Scholar
  39. 39.
    Salvatore S, Vandenplas Y. Gastroesophageal reflux and cow milk allergy: is there a link? Pediatrics. 2002;110:972–84.PubMedCrossRefGoogle Scholar
  40. 40.
    El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus. Am J Gastroenterol. 2004;99:1877–83.PubMedCrossRefGoogle Scholar
  41. 41.
    Sherman PM, Hassall E, Fagundes-Neto U, Gold BD, Kato S, Koletzko S, et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol. 2009;104:1278–95.PubMedCrossRefGoogle Scholar
  42. 42.
    Bjornsson E, Abrahamsson H, Simren M, Mattsson N, Jensen C, Agerforz P, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;24:945–54.PubMedCrossRefGoogle Scholar
  43. 43.
    Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther. 2005;21:149–54.PubMedCrossRefGoogle Scholar
  44. 44.
    Haddad I, Kierkus J, Tron E, Ulmer A, Hu P, Sloan S, et al. Efficacy and safety of rabeprazole in children (1–11 years) with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2013;57:798–807.PubMedCrossRefGoogle Scholar
  45. 45.
    Haddad I, Kierkus J, Tron E, Ulmer A, Hu P, Silber S, et al. Maintenance of efficacy and safety of rabeprazole in children aged 1–11 years with endoscopically proven GERD. J Pediatr Gastroenterol Nutr. 2014;58(4):510–7.Google Scholar
  46. 46.
    Khoshoo V, Dhume P. Clinical response to 2 dosing regimens of lansoprazole in infants with gastroesophageal reflux. J Pediatr Gastroenterol Nutr. 2008;46:352–4.PubMedCrossRefGoogle Scholar
  47. 47.
    Gilger MA, Tolia V, Vandenplas Y. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2008;46(5):524–33.PubMedCrossRefGoogle Scholar
  48. 48.
    Borrelli O, Rea P, de Bueno M, et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and lansoprazole for children with gastroesophageal reflux disease. Ital J Pediatr. 2002;28:304–9.Google Scholar
  49. 49.
    Boccia G, Manguso F, Miele E, Buonavolonta R, Staiano A. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable? Am J Gastroenterol. 2007;102:1291–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Cucchiara S, Minella R, Iervolino C, Franco MT, Campanozzi A, Franceschi M, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child. 1993;69:655–9.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Tolia V, Bishop PR, Tsou VM, Gremse D, Soffer EF, Comer GM, et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5–11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2006;42:384–91.PubMedCrossRefGoogle Scholar
  52. 52.
    Gold BD, Gunasekaran T, Tolia V, Wetzler G, Conter H, Traxler B, et al. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2007;45:520–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Tsou VM, Baker R, Book L, Hammo AH, Soffer EF, Wang W, et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clin Pediatr (Phila). 2006;45:741–9.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Jaroslaw Kierkus
    • 1
  • Grzegorz Oracz
    • 1
  • Bartosz Korczowski
    • 2
  • Edyta Szymanska
    • 3
  • Anna Wiernicka
    • 1
  • Marek Woynarowski
    • 1
  1. 1.Department of Gastroenterology, Hepatology and Feeding DisordersChildren’s Memorial Health InstituteWarsawPoland
  2. 2.Paediatric Department, State Hospital in Rzeszow, Medical CollegeUniversity of RzeszowRzeszowPoland
  3. 3.Department of Paediatrics, Nutrition and Metabolic DisordersChildren’s Memorial Health InstituteWarsawPoland

Personalised recommendations